Downregulation of long non-coding RNAs JPX and XIST is associated with the prognosis of hepatocellular carcinoma - 22/10/16

Doi : 10.1016/j.clinre.2016.09.002

Weijie Ma ^a, Haitao Wang ^a, Wei Jing ^b, Fuling Zhou ^c, Lei Chang ^a, Zhenfei Hong ^a, Hailing Liu ^d, Zhisu Liu ^a, Yufeng Yuan ^a,^⁎
^a Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Donghu Road 169#, Wuhan 430071, China
^b Department of Clinical Laboratory Medicine and Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, China
^c Department of Clinical Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China
^d Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an 710004, China

^⁎Corresponding author.

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Saturday 22 October 2016
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Highlights

•	XIST and its activator, JPX, could function as long non-coding RNA in several carcinomas.
•	Significant decreased expression level of JPX and XIST in HCC tissues and plasmas were detected which have close connection with clinical features.
•	Downregulated JPX and XIST could be candidate for novel biomarkers of poor prognosis in HCC.

Le texte complet de cet article est disponible en PDF.

Summary

Background

The expression profiles and biological relevance of long non-coding RNA XIST and its activator JPX in hepatocellular carcinoma (HCC) are not well elucidated. We measured JPX and XIST expression levels in HCC, evaluated their clinical significance in HCC progression, and verified their potential as biomarkers for diagnosing HCC.

Methods

JPX and XIST expression in 68 HCC tissues and adjacent normal tissues were evaluated by quantitative reverse transcription-PCR (qRT-PCR); their association with pathologic features and overall survival was analyzed. Plasma JPX/XIST levels in 42 patients with HCC and 68 healthy controls were measured by qRT-PCR to determine their potential as biomarkers.

Results

JPX and XIST levels were significantly decreased in HCC and associated with histological grade and tumor-node-metastasis stage (P<0.05). Low JPX and XIST expression resulted in significantly poor overall survival of HCC. Multivariate Cox regression analysis demonstrated that JPX/XIST expression levels were independent prognostic factors for HCC overall survival rates. Moreover, plasma JPX levels in patients were lower than that in controls; JPX yielded an area under the receiver operating characteristic curve of 0.814 and the combination of JPX and AFP possessed a promoted ability for discrimination between HCC patients and controls (AUC 0.905, 72.2% specificity, 97.1% sensitivity).